«If we don't have an AMC, we're going to have
lifesaving pneumococcal vaccines developed for rich countries but there's not going to be enough capacity to supply them to the poor countries,» says Orin Levine, executive director of PneumoADIP at Johns Hopkins Bloomberg School of Public Health.